Damora Therapeutics, Inc. quarterly report, Q1 FY2023

Business Context and Reporting Period

The submitted Form 10-Q is for Galecto, Inc., not Damora Therapeutics, Inc.; investors should verify the company identity. The report covers the quarter ended March 31, 2023 and was filed April 28, 2023. Galecto is a clinical-stage biotechnology company developing small-molecule inhibitors of galectin-3 and LOXL2 for fibrotic diseases and cancer. Its principal programs are GB0139, GB1211 and GB2064, all in Phase 2 development.

Financial Highlights

MetricQ1 2023Q1 2022
Product revenueNoneNone
Research and development expense$10.4 million$13.2 million
General and administrative expense$3.1 million$3.7 million
Total operating expenses$13.5 million$16.9 million
Net loss$13.0 million$16.9 million
Net loss per share$0.51$0.67
Cash used in operating activities$9.1 million$6.8 million

At March 31, 2023, cash, cash equivalents and marketable securities totaled $57.2 million, including $25.1 million of cash and cash equivalents and $32.1 million of marketable securities. Current assets were $57.1 million versus current liabilities of $14.1 million. Total assets were $64.6 million and stockholders’ equity was $50.3 million.

The filing does not report conventional funded debt. Liabilities primarily consisted of accounts payable, accrued expenses and operating lease liabilities. Total liabilities were $14.3 million, including $0.7 million of operating lease liabilities. The company had an accumulated deficit of $230.7 million.

Operating margin and gross margin are not meaningful because the company has no product revenue. Operating expenses represented the operating loss. Stock-based compensation was $1.4 million, or approximately 11% of the reported net loss.

Material Changes Versus the Prior Comparable Period

  • R&D expense declined $2.9 million, or 21.7%, primarily because of lower clinical-trial activity and chemistry, manufacturing and controls costs, partly offset by higher consultant and personnel costs.
  • G&A expense declined $0.6 million, or 15.5%, primarily due to lower insurance and other administrative costs.
  • Net loss improved by $3.9 million, or 23.3%, supported by lower operating expenses and $0.5 million of net other income, including higher interest income.
  • Cash used in operations increased $2.3 million despite the lower net loss, reflecting working-capital timing and changes in accrued expenses and prepaid costs.
  • Cash, cash equivalents and marketable securities declined from $66.1 million at December 31, 2022 to $57.2 million at March 31, 2023.
  • The company sold 21,082 shares through its at-the-market program for net proceeds of approximately $23,000.

Outlook, Clinical Developments and Risks

  • Management expects existing cash, cash equivalents and marketable securities to fund operating and capital requirements into the second half of 2024, subject to assumptions that may prove incorrect.
  • Additional financing will be required to continue development. Potential sources include equity or debt offerings, licensing, partnerships and collaborations. Additional equity financing would dilute existing holders.
  • For GB0139, enrollment in the 144-patient GALACTIC-1 Phase 2b IPF trial was complete, with topline results expected in August 2023.
  • For GB1211, the GALLANT-1 NSCLC trial was ongoing. Two serious autoimmune-type skin events occurred among the first seven patients receiving the higher dose; investigators attributed them to atezolizumab, and the events were clinically manageable. Interim safety data were expected in the second half of 2023 and topline results in the first half of 2024.
  • For GB2064, the MYLOX-1 trial had enrolled and treated 18 patients. Enrollment was stopped after the predefined antifibrotic activity target was exceeded, with topline results expected in the second half of 2023.
  • Key risks include failure or delay of clinical trials, safety or efficacy issues, regulatory nonapproval, manufacturing and supply constraints, intellectual-property challenges, dependence on third parties and key personnel, competition, and inability to raise capital.
  • The company identified no material changes to previously disclosed risk factors, no material legal proceedings and no material subsequent events. Management concluded that disclosure controls and procedures were effective at the reasonable-assurance level.

Important Facts for Investors to Verify

  • Confirm the apparent issuer mismatch: the filing text identifies Galecto, Inc. and ticker GLTO, while the request identifies Damora Therapeutics, Inc.
  • Verify the cash runway assumptions and the timing and terms of any future financing.
  • Review topline and safety results for GALACTIC-1, GALLANT-1 and MYLOX-1 when available.
  • Assess the clinical significance and durability of reported partial responses, biomarker changes and fibrosis reductions, which are preliminary and not regulatory approvals.
  • Monitor dilution from the ATM program, stock options and any future equity issuance; 7.55 million stock options were outstanding at March 31, 2023.
  • Confirm that no product candidate has been approved for sale and that the company has not generated product revenue.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.